Credit Suisse Ag Ginkgo Bioworks Holdings, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Ginkgo Bioworks Holdings, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 1,145,933 shares of DNA stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,145,933

Previous 1,205,245 4.92%

Holding current value

$10.8 Million

Previous $2.04 Million 34.72%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.06 - $1.67 $62,870 - $99,051	-59,312 Reduced 4.92%	1,145,933 $1.33 Million
Q4 2023 Feb 08, 2024	BUY	$1.26 - $1.79 $99,396 - $141,205	78,886 Added 7.0%	1,205,245 $2.04 Million
Q3 2023 Nov 13, 2023	BUY	$1.61 - $2.54 $164,211 - $259,067	101,995 Added 9.96%	1,126,359 $2.04 Million
Q2 2023 Aug 11, 2023	SELL	$1.14 - $1.95 $153,697 - $262,902	-134,822 Reduced 11.63%	1,024,364 $1.91 Million
Q1 2023 May 10, 2023	BUY	$1.2 - $2.19 $314,571 - $574,093	262,143 Added 29.22%	1,159,186 $1.54 Million
Q4 2022 Feb 13, 2023	BUY	$1.63 - $3.52 $219,223 - $473,415	134,493 Added 17.64%	897,043 $1.52 Million
Q3 2022 Nov 10, 2022	BUY	$0.73 - $3.74 $44,639 - $228,701	61,150 Added 8.72%	762,550 $2.38 Million
Q2 2022 Aug 12, 2022	BUY	$2.2 - $4.2 $1 Million - $1.91 Million	454,767 Added 184.39%	701,400 $1.67 Million
Q1 2022 May 16, 2022	BUY	$2.83 - $8.69 $310,459 - $953,319	109,703 Added 80.12%	246,633 $994,000
Q4 2021 Feb 14, 2022	BUY	$8.31 - $14.92 $1.14 Million - $2.04 Million	136,930 New	136,930 $1.14 Million

Others Institutions Holding DNA

# of Institutions

Shares Held

48.1M

Call Options Held

Put Options Held

View Full List

About Ginkgo Bioworks Holdings, Inc.

Ticker DNA
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,287,779,968
Market Cap $12.2B
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...

More about DNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account